BioLargo's Net Loss Widens to $11M Amidst Revenue Plunge, Credit Loss

TL;DR

**BLGO is bleeding cash and revenue, with a massive credit loss, making it a high-risk bet for any investor.**

AI Summary

BIOLARGO, INC. (BLGO) reported a significant net loss of $11.047 million for the nine months ended September 30, 2025, a substantial increase from the $2.615 million loss in the prior year period. This was primarily driven by a $3.849 million credit loss expense from a customer's contractual defaults, which is now subject to litigation. Total revenue decreased sharply to $7.148 million for the nine months ended September 30, 2025, down from $14.122 million in the same period of 2024, with product revenue falling from $13.397 million to $5.584 million. Operating loss widened to $10.844 million from $2.715 million year-over-year. The company used $6.707 million in net cash from operating activities but received $7.269 million from financing activities, including $2.145 million from Clyra Medical preferred series B and $1.894 million from Clyra unit warrant offering. As of September 30, 2025, BLGO had $4.546 million in cash and cash equivalents and working capital of $2.324 million, but management expressed substantial doubt about its ability to continue as a going concern without increased revenues or further investment capital.

Why It Matters

This filing reveals significant financial distress for BioLargo, with a substantial net loss and declining revenue raising going concern doubts. For investors, the 50% drop in total revenue and the $3.849 million credit loss expense signal severe operational challenges and potential write-downs, impacting future profitability and stock value. Employees might face job insecurity if the company curtails operations due to capital constraints. Customers could see disruptions in service or product availability if the company struggles to fund its business plans. In the competitive environmental technology market, BioLargo's liquidity issues could hinder its ability to develop and commercialize its innovative platform technologies, potentially ceding market share to better-capitalized rivals.

Risk Assessment

Risk Level: high — The company reported a net loss of $11.047 million for the nine months ended September 30, 2025, and used $6.707 million in net cash from operating activities. Management explicitly stated, "The foregoing factors raise substantial doubt about our ability to continue as a going concern, unless we are able to increase revenues, generate cash from operations, and/or generate cash from financing activities."

Analyst Insight

Investors should exercise extreme caution and consider divesting or avoiding BLGO shares due to the explicit 'going concern' warning, significant net losses, and declining revenues. Monitor the outcome of the litigation related to the $3.849 million credit loss and any new financing activities, as these will be critical for the company's survival.

Financial Highlights

debt To Equity

1.84

revenue

$7,148,000

operating Margin

-151.7%

total Assets

$9,130,000

total Debt

$11,948,000

net Income

-$11,047,000

eps

N/A

gross Margin

-39.6%

cash Position

$4,546,000

revenue Growth

-49.4%

Revenue Breakdown

Key Numbers

• $11.047M — Net Loss (Increased from $2.615M in prior year period for nine months ended Sept 30, 2025)
• $3.849M — Credit Loss Expense (Resulting from customer contractual defaults for nine months ended Sept 30, 2025)
• $7.148M — Total Revenue (Decreased from $14.122M in prior year period for nine months ended Sept 30, 2025)
• $6.707M — Net Cash Used in Operating Activities (For nine months ended Sept 30, 2025)
• $7.269M — Net Cash Provided by Financing Activities (For nine months ended Sept 30, 2025)
• $4.546M — Cash and Cash Equivalents (As of September 30, 2025)
• $2.324M — Working Capital (As of September 30, 2025)
• 313,762,657 — Common Stock Outstanding (As of November 12, 2025)

Key Players & Entities

• BIOLARGO, INC. (company) — registrant
• Clyra Medical Technologies, Inc. (company) — partially owned subsidiary
• BioLargo Engineering Science and Technologies, LLC (company) — partially owned subsidiary
• BioLargo Energy Technologies, Inc. (company) — partially owned subsidiary
• Securities and Exchange Commission (regulator) — filing oversight
• Bloomberg (company) — publisher

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: Management has expressed substantial doubt about the company's ability to continue as a going concern due to significant net losses and declining revenues. This uncertainty persists without increased revenues or further investment capital.
• Credit Loss Litigation [high — legal]: A $3.849 million credit loss expense was recognized due to a customer's contractual defaults, which is now subject to litigation. This legal entanglement poses financial and operational risks.
• Deteriorating Financial Performance [high — financial]: The company reported an $11.047 million net loss for the nine months ended September 30, 2025, a substantial increase from $2.615 million in the prior year. Total revenue plummeted to $7.148 million from $14.122 million.
• Dependence on Key Customers [medium — operational]: The significant credit loss expense stemming from a single customer's default highlights a potential over-reliance on a few key clients, making the company vulnerable to their financial health and contractual adherence.
• Negative Working Capital Trend [medium — financial]: While working capital was $2.324 million as of September 30, 2025, the sharp decline in revenue and significant operating losses are pressuring liquidity. The company's ability to manage short-term obligations is a concern.
• Increased Operating Expenses [medium — financial]: The operating loss widened to $10.844 million from $2.715 million year-over-year, indicating that operating expenses are not scaling down proportionally with revenue, exacerbating the net loss.

Industry Context

BIOLARGO operates in the environmental technology and medical device sectors. The environmental sector is characterized by increasing regulatory scrutiny and demand for sustainable solutions. The medical device sector is highly competitive, driven by innovation, regulatory approvals, and market access. Companies in these fields often face long development cycles and significant R&D investments.

Regulatory Implications

The company's operations, particularly in environmental solutions, may be subject to various environmental regulations. Any product claims or marketing related to medical devices would fall under FDA or equivalent international body oversight. Non-compliance could lead to fines, product recalls, or operational shutdowns.

What Investors Should Do

1. Monitor litigation outcome
2. Assess cash burn rate
3. Evaluate revenue recovery potential
4. Scrutinize financing activities

Key Dates

• 2025-09-30: End of Nine-Month Period — Reporting period for the significant net loss of $11.047 million and revenue of $7.148 million.
• 2025-09-30: Balance Sheet Date — Company reported $4.546 million in cash and $2.324 million in working capital, with management expressing going concern doubts.
• 2025-11-12: Common Stock Outstanding Date — 313,762,657 shares of common stock outstanding, indicating a potentially diluted share structure.

Glossary

Accumulated deficit

The total cumulative net losses of a company since its inception, minus any cumulative net income. (Indicates the company has historically incurred more losses than profits, standing at ($158,327,000) as of September 30, 2025.)

Going concern

An assumption that a company will continue to operate for the foreseeable future, typically at least the next 12 months. (Management's doubt about this status highlights severe financial distress and potential for bankruptcy.)

Credit loss expense

An expense recognized for the estimated losses on loans or receivables that are unlikely to be collected. (A significant $3.849 million expense due to customer defaults is a major driver of the current period's net loss.)

Working capital

The difference between a company's current assets and current liabilities, indicating its short-term financial health. (A positive working capital of $2.324 million exists, but its sustainability is questionable given the operating losses.)

Non-controlling interest

The portion of equity in a subsidiary that is not attributable to the parent company. (A negative non-controlling interest of ($3,365,000) suggests potential future obligations or losses attributed to minority shareholders.)

Year-Over-Year Comparison

For the nine months ended September 30, 2025, BIOLARGO, INC. experienced a dramatic downturn compared to the prior year. Total revenue fell by nearly 50% from $14.122 million to $7.148 million, primarily due to a collapse in product revenue. This revenue decline, coupled with a significant $3.849 million credit loss expense, led to a net loss widening from $2.615 million to $11.047 million. Operating margins have severely deteriorated, reflecting the challenging financial performance.

Key Financial Figures

• $250,000 — nsurance Corporation insurance limit of $250,000 per owner per bank, and during such tim

Filing Documents

• blgo20250930_10q.htm (10-Q) — 2272KB
• ex_856736.htm (EX-31.1) — 10KB
• ex_856737.htm (EX-31.2) — 10KB
• ex_856738.htm (EX-32) — 10KB
• 0001437749-25-035239.txt ( ) — 11430KB
• blgo-20250930.xsd (EX-101.SCH) — 80KB
• blgo-20250930_cal.xml (EX-101.CAL) — 53KB
• blgo-20250930_def.xml (EX-101.DEF) — 632KB
• blgo-20250930_lab.xml (EX-101.LAB) — 502KB
• blgo-20250930_pre.xml (EX-101.PRE) — 666KB
• blgo20250930_10q_htm.xml (XML) — 2309KB

Financial Statements

Financial Statements 1 Item 2

Management's Discussion and Analysis and Financial Condition and Results of Operations

Management's Discussion and Analysis and Financial Condition and Results of Operations 27 Item 4

Controls and Procedures

Controls and Procedures 38 PART II Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 40 Item 5 Other Information 40 Item 6 Exhibits 41

Signatures

Signatures 43 Table of Contents

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements - 1 - Table of Contents BIOLARGO, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except for share and per share data) September 30, 2025 December 31, (unaudited) 2024 Assets Current assets: Cash and cash equivalents $ 4,546 $ 3,548 Accounts receivable, net of allowances 761 3,168 Inventories 409 330 Prepaid expenses and other current assets 59 91 Total current assets 5,775 7,137 Equipment and leasehold improvements, net 1,664 1,742 Other non-current assets 116 95 Operating lease right-of-use assets, net 1,070 992 Financing lease right-of-use asset, net 400 451 Clyra Medical note receivable 82 82 Investment in South Korean joint venture 23 14 Total assets $ 9,130 $ 10,513 Liabilities and stockholders' equity Current liabilities: Accounts payable and accrued expenses $ 891 $ 946 Clyra Medical accounts payable and accrued expenses 1,134 867 Clyra Medical debt obligations, net of discount $ 161 and $ 80 1,033 486 Debt obligations 83 66 Operating lease liabilities 142 105 Finance lease liability 88 88 Deposits 80 90 Total current liabilities 3,451 2,648 Long-term liabilities: Debt obligations, net of current 190 175 Clyra Medical debt obligations, net of current and discount $ 55 and $ 80 1,010 352 Operating lease liabilities, net of current 969 922 Finance lease liability, net of current 295 360 Total long-term liabilities 2,464 1,809 Total liabilities 5,915 4,457 STOCKHOLDERS' EQUITY: Preferred Series A, $ 0.00067 Par Value, 50,000,000 Shares Authorized, no Shares Issued and Outstanding, at September 30, 2025 and December 31, 2024 — — Common stock, $ 0.00067 Par Value, 550,000,000 Shares Authorized, 311,452,683 and 301,274,243 Shares Issued, at September 30, 2025 and December 31, 2024 208 202 Additional paid-in capital 164,894 158,332 Accumulated deficit ( 158,327 ) ( 149,500 ) Accumulated other c

View Full Filing

View this 10-Q filing on SEC EDGAR